Navigation Links
Chindex International, Inc. Reports First Quarter 2013 Financial Results

BETHESDA, Md., May 8, 2013 /PRNewswire/ -- Chindex International, Inc. (NASDAQ: CHDX), an American health care company providing health care services in China through the operations of United Family Healthcare ("UFH"), a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the first quarter of 2013 ended March 31, 2013.

First Quarter 2013 Financial Highlights

  • Revenue from healthcare services increased 28% to $41.6 million from $32.5 million in the prior year period.
  • Adjusted EBITDA rose by 36% to $7.4 million from $5.5 million in the prior year period.
  • Development, pre-opening and start-up expense was $2.5 million compared to $3.2 million in the prior year period.
  • Income from operations increased 313% to $2.6 million from $625,000 in the prior year period.
  • Net loss was $62,000, or $0.00 per diluted share, compared to net loss of $531,000, or $(0.03) per diluted share, in the prior year period.
  • Roberta Lipson, President and CEO of Chindex, commented, "I'm pleased to have started 2013 with strong top-line, operating income and adjusted EBITDA growth in the first quarter. Results were primarily driven by increased patient traffic at UFH's expanded network. Our oncology, cardio and neurosurgery surgical units, while still in their early stages of development, are drawing healthy levels of patients and improving  profitability as income from operations more than tripled to $2.6 million, and adjusted EBITDA rose by 36% to $7.4 million, representing 18% adjusted EBITDA margin. We continue to experience growing patient demand for healthcare services both among Chinese nationals and expatriates reinforcing our expansion plans to meet the underserved demand for premium private healthcare sst of the following:Change in property and equipment additions included in accounts payable


    $216 The table below reconciles our consolidated net loss to Adjusted EBITDA (in thousands)Three months ended March 31,20132012Consolidated net loss


    $(531)Adjustments:Depreciation and amortization


    1,651Provision for income taxes


    1,259Interest expense


    124Interest and other income, net


    (129)Development, pre-opening and start-up expense


    3,203Equity in loss (income) of unconsolidated affiliate



    6,010Adjusted EBITDA



    ervices in China."

    "During the first quarter, we continued to move forward with our ramp up of new facilities and service lines. The Beijing United Family Rehabilitation Hospital has secured the required regulatory approvals, has staff and equipment in place, and is scheduled to open for Phase I operations in June 2013. Our new facilities and services in Beijing are all ramping up quickly and we are working on future expansion in both areas. In Shanghai, we are working on a new facility in Puxi and evaluating a potential new hospital site as well. Encouraged by the positive response to our newly launched Home Healthcare service in Beijing, we have launched this service in Tianjin at the end of the first quarter and plan to expand the program to Shanghai later this year."

    "We believe Chindex can continue growing at a rapid pace for the remainder of this year. Our strategic priorities will focus on the continued growth of existing facilities, ramping up new facilities and services lines, and expanding across geographies and service offerings. While these efforts may take some time to drive high consolidated growth rates, we reiterate comfort with our full year revenue percentage growth rates in the mid-high twenties and adjusted EBITDA growth in the mid-high teens."

    First Quarter 2013 Financial ResultsFirst quarter 2013 revenue from healthcare services increased 28% to $41.6 million from $32.5 million in the prior year period. These results reflect continued growth of inpatient and outpatient volume across the United Family Healthcare network as well as increasing contributions from the expansion of the Company's flagship hospital in Beijing. Outpatient services contributed 57% and inpatient services contributed 43% of revenue, compared with 62% and 38%, respectively, in the prior year period. By service line, surgical services contributed 18.1%, OB/GYN contributed 15.8%, pediatrics contributed 8.5%, ancillary services contributed 31.9% and other clinical service lines contributed 25.7% of revenue.

    Operating expenses in the first quarter of 2013 increased 22% to $39.0 million from $31.9 million in the prior year period. These costs were primarily driven by the Company's recently opened expansions as well as development of new facilities. Salaries, wages and benefits in the first quarter of 2013 increased 22% to $22.7 million from $18.6 million in the prior year period, reflecting a 26% increase in headcount to support revenue growth and development activities, including newly recruited staff now on-board in anticipation of the opening of the Beijing United Family Rehabilitation Hospital. Development, pre- and post-opening and start-up expenses were $2.5 million this quarter, compared to $3.2 million for the prior year period. These expenses were driven by development projects across all markets, including particularly the Beijing United Family Rehabilitation Hospital and the ramp-up of Tianjin United Family Hospital. Operating expenses also included certain non-cash expenses including $790,000 of stock-based compensation expense compared to $614,000 for the prior year period.

    Adjusted EBITDA in the first quarter of 2013 increased 36% to approximately $7.4 million from $5.5 million in the prior year period. The Adjusted EBITDA results illustrate the consistent and improving profitability and expanding earnings base of existing UFH facilities.

    Income from operations increased to $2.6 million from $625,000 in the prior year period.

    The Company recorded a $1.9 million provision for taxes in the first quarter of 2013 compared to $1.3 million in the prior year period. As in past quarters, the current period provision continued to be heavily impacted by losses in development and start-up entities for which the Company cannot currently recognize tax benefits.

    Net loss for the quarter ended March 31, 2013 was $62,000, or $0.00 per diluted share, compared to net loss of $531,000, or $(0.03) per diluted share, in the prior year period. For the first quarter of 2013, weighted average diluted shares outstanding were 16.5 million.

    As of March 31, 2013, the Company had $31.4 million in unrestricted cash, cash equivalents and investments.

    Chindex Medical LimitedFor Chindex Medical Limited (CML), a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") and Chindex International, Chindex recognized its 49% interest in CML's net income using the equity method of accounting. In the first quarter ended March 31, 2013, Chindex recognized a loss of $900,000, for its 49% equity in the operating results of CML. This consisted of a loss of $771,000, for the stand-alone net income (loss) of CML (after recognition of stock-based compensation expense) and after deducting $129,000, for the amortization of basis differences attributable to acquired intangibles.

    Non-GAAP MeasuresThe Company presents Adjusted EBITDA to better illustrate ongoing operational results. Adjusted EBITDA is defined as income (loss) before interest expense, interest and other income, income taxes, depreciation and amortization, and also excludes development, pre-opening and start-up expenses related to new and pending hospitals and clinics, equity in earnings (loss) income of unconsolidated affiliate, non-recurring charges for Chindex Medical Limited (CML) joint venture formation. The Company anticipates recurring development, pre-opening and start-up expense and notes that such expense is a basic element of the long term growth plan. Management believes that providing an Adjusted EBITDA analysis to investors is a helpful metric to better illustrate the Company's operations, including development plans, and changes in presentation from historical periods. The Company uses Adjusted EBITDA for business planning and other purposes. Other companies may calculate Adjusted EBITDA differently, and therefore Chindex's Adjusted EBITDA may not be comparable to similarly titled measures of other companies. Adjusted EBITDA is not a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and should not be considered in isolation or as an alternative to net income (loss), cash flows from operating activities and other measures determined in accordance with GAAP. Items excluded from Adjusted EBITDA are significant and necessary components to the operations of the Company's business, and, therefore, Adjusted EBITDA should only be used as a supplemental measure of operating performance.

    Conference Call Management will host a conference call at 8:00 am ET Thursday morning on May 9, 2013 to discuss financial results. To participate in the conference call, U.S. domestic callers may dial 1-877-303-9231 and international callers may dial 1-760-666-3567 approximately 10 minutes before the conference call is scheduled to begin. The conference ID is 55024835. A webcast and replay of the earnings call will be accessible via Chindex's website at

    About Chindex International, Inc.Chindex is an American health care company providing health care services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. United Family Healthcare currently operates in Beijing, Shanghai, Tianjin and Guangzhou. The Company also provides medical capital equipment and products through Chindex Medical Ltd., a joint venture company with manufacturing and distribution businesses serving both domestic China and export markets. With more than thirty years of experience, the Company's strategy is to continue its growth as a leading integrated health care provider in the Greater China region. Further Company information may be found at the Company's website at

    Safe Harbor Statement Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, updates and additions to those "Risk Factors" in the Company's interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.


    ICR, Inc.
    Bill Zima
    (+86) 10-6583-7511
    (646) 328-2510

    Financial Summary AttachedCHINDEX INTERNATIONAL, INC.CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS(in thousands except share and per share data)(Unaudited)Three months ended March 31,2013
    2012Healthcare services revenue


    $32,512Operating expensesSalaries, wages and benefits


    17,306Other operating expenses


    4,429Supplies and purchased medical services


    4,124Bad debt expense


    735Depreciation and amortization


    1,492Lease and rental expense



    31,887Income from operations


    625Other income and (expenses)Interest income


    251Interest expense


    (355)Equity in (loss) income of unconsolidated affiliate


    98Miscellaneous (expense) - net


    (10)Income before income taxes


    728Provision for income taxes


    (1,259)Net loss


    $(531)Net loss  per common share - basic


    $(.03)Weighted average shares outstanding - basic


    16,291,792Net loss per common share - diluted


    $(.03)Weighted average shares outstanding - diluted


    16,291,792 CHINDEX INTERNATIONAL, INC.CONSOLIDATED CONDENSED BALANCE SHEETS(in thousands, except share data)(Unaudited)March 31, 2013December 31, 2012ASSETSCurrent assets: Cash and cash equivalents


    $33,184 Restricted cash


    754Accounts receivable, less allowance for doubtful accounts of $11,621 
    and $10,612, respectively


    19,564Receivables from affiliates


    2,110 Inventories of supplies, net


    2,328 Deferred income taxes


    3,209 Other current assets


    3,798Total current assets


    64,511Restricted cash and sinking funds


    20,351Investment in unconsolidated affiliate


    34,847Property and equipment, net


    97,952Noncurrent deferred income taxes


    925Other assets


    3,428Total assets


    $222,450LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Short-term debt


    $1,586Accounts payable


    9,520Payable to affiliates


    1,334Accrued expenses


    15,540Other current liabilities


    8,558Income taxes payable


    2,772Total current liabilities


    39,310Long-term debt and convertible debentures


    32,812Long-term deferred tax liability


    262Total liabilities


    72,384Commitments and contingenciesStockholders' equity: Preferred stock, $.01 par value, 500,000 shares authorized, none issued


    -Common stock, $.01 par value, 28,200,000 shares authorized, including 3,200,000 designated Class B:Common stock - 15,902,784 and 15,904,836 shares issued andoutstanding at March 31, 2013 and December 31, 2012, respectively


    159 Class B stock - 1,162,500 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively


    12Additional paid-in capital


    122,109Retained earnings


    18,583Accumulated other comprehensive income


    9,203Total stockholders' equity


    150,066Total liabilities and stockholders' equity


    $222,450 CHINDEX INTERNATIONAL, INC.CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS(in thousands)(Unaudited)Three months ended March 31, 2013


    $(531)Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization


    1,651Inventory write down


    11Provision for doubtful accounts


    765Loss on disposal of property and equipment


    5Equity in (loss) income of unconsolidated affiliate


    (98)Deferred income taxes


    (126)Stock based compensation


    614Foreign exchange loss


    214Amortization of debt issuance costs


    2Amortization of debt discount


    62Changes in operating assets and liabilities:Restricted cash


    1,052Accounts receivable


    (2,333)Accounts receivable from affiliates


    (583)Inventories of supplies


    421Other current assets and other assets


    (1,630)Accounts payable, accrued expenses, other current liabilities and deferred revenue


    1,192Accounts payable to affiliates


    1,609Income taxes payable


    99Net cash provided by operating activities


    2,396INVESTING ACTIVITIESProceeds from redemption of CDs


    21,970Purchases of property and equipment


    (7,141)Net cash (used in) provided by investing activities


    14,829FINANCING ACTIVITIESRestricted cash for IFC RMB loan sinking funds


    (12,051)Repayment of debt


    -Proceeds from exercise of stock options


    16Net cash used in financing activities


    (12,035)Effect of foreign exchange rate changes on cash and cash equivalents


    10Net (decrease) increase in cash and cash equivalents


    5,200Cash and cash equivalents at beginning of period


    33,755Cash and cash equivalents at end of period


    $38,955Supplemental disclosures of cash flow information:Cash paid for interest


    $-Cash paid for taxes


    $1,289Non-cash investing and financing activities consi

    SOURCE Chindex International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Chindex-Fosun Pharma Joint Venture, Chindex Medical, To Participate in Acquisition of Alma Lasers; Fosun Pharma Increases Investment in Chindex Medical
    2. Chindex International, Inc. to Announce Participation in Upcoming Investor Conferences
    3. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2012
    4. Chindex International, Inc. to Report First Quarter 2012 Financial Results
    5. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
    6. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
    7. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
    8. VWR International, LLC Acquires Basan UK Limited
    9. VWR International, LLC Acquires Prolab Laboratuar Teknolojileri Limited In Turkey
    10. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
    11. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
    Post Your Comments:
    (Date:10/9/2015)... October 9, 2015 ... sich einer Kolonoskopie im Rahmen eines Screenings, ... Die NOCT-Studie bewertete auch die Compliance, Sicherheit, ... ® ) an erwachsenen Patienten vergleicht, ... Screenings, einer beobachtenden oder einer diagnostischen Kolonoskopie ...
    (Date:10/9/2015)... -- --> --> ... of an Intellectual Property & Subsidiary Assignment and an Assignment & Assumption ... Corporation, related party, and a majority holder of 88% ... --> These agreements were executed as part of ... and Development components shall now be separate from the ...
    (Date:10/9/2015)... India , October 9, 2015 ... --> The report ... market and overall status of the ... of guidance and direction for companies ... . ...
    Breaking Medicine Technology:
    ... /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and ... Shareholder Meeting to the 26th floor, Conference Room E ... (EDT). Shareholders will be admitted beginning at 9:30 am. ...
    ... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... that it has scheduled a conference call ... to discuss the Company,s financial results for its fourth ...   Bacterin International Holdings, Inc. intends to issue its earnings ...
    Cached Medicine Technology:
    (Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
    (Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify ... available online ( ) – just in time for the cold and flu ... October. However, for many in the U.S., the real start of cold/flu season is ...
    (Date:10/9/2015)... ... October 09, 2015 , ... ... promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. This alternative ... invisible against the teeth, which allow patients to complete treatment in privacy. Additionally, ...
    (Date:10/9/2015)... Washington, DC (PRWEB) , ... October 09, 2015 , ... ... agreement from the US Centers for Disease Control and Prevention (CDC) to improve the ... 14 years that AAFA has been awarded a project by the CDC and allows ...
    (Date:10/9/2015)... Ohio (PRWEB) , ... October 09, 2015 , ... ... United States, is welcoming individuals from all walks of life to save money ... the set price of $25 per month per medication, individuals and families can ...
    Breaking Medicine News(10 mins):
    ... 12 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... on February 19, 2009, and will host a conference call to ... Eastern Time. , , , Date: ... Time, Conference call access:, Internet: ...
    ... Pamper Tired TootsiesBETHESDA, Md., Feb. 12 Valentine,s Day marks ... men and women. While the old adage "a way to ... true, another body part is gaining affection from both sexes ... (APMA) survey revealed 84 percent of women are embarrassed about ...
    ... MediCom Worldwide, Inc., an accredited provider of continuing medical ... of an online repository of resources and education on ... of health care practitioners.The goal of Managing ... to provide an extensive array of programs to support ...
    ... Scientists studying an inherited condition resulting in blindness and ... affect both eye function and normal tooth development. ... the formation of teeth and eyes has been uncovered ... in two families living in a village in the ...
    ... a key role in the prevention and treatment of ... Endothelial cells line the blood vessels and are critical ... , Researchers at the Centenary Institute have discovered ... cells. , Professor Jenny Gamble, Head of ...
    ... research will focus increasingly on electronic data, with less ... long term trend emerged at a recent conference on ... dealt with the challenges posed by the growing scale ... But in the more immediate future biological specimens will ...
    Cached Medicine News:
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: